By Chris Wack
Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500.
The clinical-stage biopharmaceutical company said VIR-5818 targets HER2-expressing solid tumors, showing tumor shrinkage in 50% of heavily pretreated participants, with no significant adverse events.
VIR-5818 is being tested alone and with pembrolizumab across various cancers, including breast and colorectal cancer.
The San Francisco company said VIR-5500, for metastatic castration-resistant prostate cancer, has shown PSA reductions in all participants.
Both drugs exhibit favorable safety profiles with no dose-limiting cytokine release syndrome or toxicities, suggesting effective tumor-specific activation due to the PRO-XTEN masking technology. Both studies continue dose escalation, with no maximum tolerated dose yet determined, and are exploring less frequent dosing due to prolonged drug half-life.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 08, 2025 10:14 ET (15:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。